NutriBand Inc.
NTRBWNasdaq
$0.52
0.0%Jul 17 close · end-of-day
Price
1Y↓ -82.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.3M
Enterprise Value
$2.3M
P/E
—
P/S
3.5
P/B
1.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$1.8M
Net Income (TTM)
-$8.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-452.6%
Net Margin
-448.4%
ROE
-134.9%
ROIC
-324.9%
Debt / Equity
—
Net Cash
$4.0M
Return 1Y
-82.1%
Company profile
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl system.
- CEO
- Gareth R. Sheridan
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 10
- Headquarters
- Florida
- Website
- nutriband.com
Earnings
NTRBW Q1 2026 Earnings
Period ends 2026-04-30
MetricActualYoY
Revenue$433,399.00↓ -35.1%
Diluted EPS-$0.10↓ -16.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $943,702.00 | $1.4M | $2.1M | $2.1M | $2.1M | $2.0M |
| Gross profit | $316,234.00 | $554,310.00 | $750,404.00 | $862,105.00 | $743,317.00 | $566,308.00 |
| Operating income | -$2.6M | -$6.1M | -$4.5M | -$4.9M | -$10.3M | -$8.3M |
| Net income | -$2.9M | -$6.2M | -$4.5M | -$5.5M | -$10.5M | -$8.2M |
| Diluted EPS | — | -$0.80 | -$0.53 | -$0.69 | -$0.99 | -$2.58 |
| Operating cash flow | -$297,055.00 | -$2.8M | -$3.0M | -$3.5M | -$4.6M | -$5.1M |
| Free cash flow | — | -$2.9M | -$3.1M | -$3.6M | -$4.7M | -$5.1M |
| Gross margin | 33.5% | 39.0% | 36.1% | 41.3% | 34.7% | 27.8% |
| Operating margin | -275.1% | -429.7% | -215.2% | -233.6% | -480.7% | -408.4% |
| Net margin | -310.8% | -434.3% | -215.6% | -263.0% | -489.9% | -404.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '26 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $442,830.00 | $645,796.00 | $642,379.00 | $667,432.00 | $622,452.00 | $346,058.00 | $400,709.00 | $433,399.00 |
| Gross profit | $101,558.00 | $191,029.00 | $285,944.00 | $251,981.00 | $156,881.00 | $68,505.00 | $88,941.00 | — |
| Operating income | -$1.4M | -$1.4M | -$5.6M | -$1.4M | -$2.0M | -$3.9M | -$1.0M | -$1.3M |
| Net income | -$1.7M | -$1.4M | -$5.5M | -$1.4M | -$2.0M | -$3.9M | -$968,059.00 | -$1.2M |
| Diluted EPS | -$0.15 | -$0.12 | -$0.51 | -$0.12 | -$2.12 | -$0.32 | -$0.02 | -$0.10 |
| Operating cash flow | -$1.5M | -$1.0M | -$1.2M | -$1.3M | -$1.3M | -$1.8M | -$731,830.00 | -$563,104.00 |
| Free cash flow | -$1.6M | -$1.1M | -$1.2M | -$1.3M | -$1.3M | -$1.8M | -$731,830.00 | — |
| Gross margin | 22.9% | 29.6% | 44.5% | 37.8% | 25.2% | 19.8% | 22.2% | — |
| Operating margin | -318.3% | -220.9% | -865.3% | -211.8% | -321.8% | -1121.3% | -254.8% | -289.4% |
| Net margin | -385.1% | -211.0% | -858.8% | -208.1% | -321.4% | -1119.0% | -241.6% | -286.6% |
Company news
Mar 30, 2026
Mar 18, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.